Table 1.
Baseline Clinical Characteristics of Patients
| Characteristics | Value |
|---|---|
| Gender, n (%) | |
| Male | 8(80.0) |
| Mean±SD | 58.7±7.85 |
| Female | 2(20.0) |
| Age (years) | |
| Median | 56 |
| Range | 46–71 |
| Weight | |
| ≥60kg | 5(50.0) |
| <60kg | 5(50.0) |
| Etiology, n (%) | |
| HBV | 3(30.0) |
| Unknow | 7(70.0) |
| ECOG, n (%) | |
| 1 | 7(70.0) |
| 2 | 3(30.0) |
| Child–Pugh class, n (%) | |
| A | 7(70.0) |
| B | 3(30.0) |
| Serum CA19-9, n (%) | |
| ≥27U/mL | 6(60.0) |
| <27U/mL | 4(40.0) |
| Tumor size(cm), n (%) | |
| Mean±SD | 6.84±4.41 |
| ≥5cm | 7(70.0) |
| <5cm | 3(30.0) |
| Number of tumors, n (%) | |
| 1–3 | 4(40.0) |
| >3 | 6(60.0) |
| Macroscopic vascular invasion, n (%) | |
| Yes | 3(30.0) |
| No | 7(70.0) |
| Metastatic sites, n (%) | |
| Regional lymph nodes | 10(100.0) |
| Distant lymph nodes | 3(30.0) |
| Lung | 6(60.0) |
| Bone | 4(40.0) |
| Biliary drainage | |
| Yes | 2(20.0) |
| No | 8(80.0) |
| Previous therapy, n (%) | |
| No | 5(50.0) |
| Chemotherapy | 1(10.0) |
| Radiotherapy | 1(10.0) |
| Resection and chemoradiotherapy | 2(20.0) |
| TACE | 1(10.0) |
| Disease stage, n (%) | |
| IIIB | 3(30.0) |
| IV | 7(70.0) |
Abbreviations: HBV, hepatitis B virus; ECOG, Eastern Cooperative Oncology Group; CA19-9, carbohydrate antigen 19–9; TACE, transarterial chemoembolization.